NIDA CTN Research Updates: Treatments for Stimulant Use Disorders
-
Register
- Non-Member - $39
- Regular Member - $29
- Retired - $29
- Early Career Physician - $29
- Resident - $19
- Student - $19
- Associate - $19
- ASAM Staff - Free!
- International Member - $29
- Emeritus Member - $29
- Provisional Member - $29
- Fellow Member - $29
- Honorary Member - $29
- CRT Member - $29
NIDA CTN Research Updates: Treatments for Stimulant Use Disorders
Developed in Collaboration with the National Institute on Drug Abuse
Recorded: Thursday, April 4, 2024 to Sunday, April 7, 2024
On-Demand Session
Overview
This 75-minute on-demand session from the ASAM 55th Annual Conference addresses pharmacotherapy options for the management of stimulant use disorders.
There are no FDA approved medications for the management of stimulant use disorders. However, preliminary and emerging evidence from the NIDA Clinical Trials Network exploring the role of medications and other interventions in the management of these disorders, provide suggestions for novel pathways and potential new effective treatments.
The target audience for this Intermediate level session includes physicians, nurse practitioners, physician assistants, other clinicians, researchers, residents, fellows, students, and counselors.
This session addresses the following ACGME Competencies: Medical Knowledge
This session addresses the following ICPE Competencies:Roles and Responsibilities
Learning Objectives
Upon completion, learners will be able to:
- Upon completion of the focus session, the participant will be able to demonstrate an increased knowledge of pharmacotherapy options for the management of stimulant use disorders.
- Upon completion of the focus session, the participant will be able to discover the mechanisms and utility of brain stimulation techniques including transcranial magnetic stimulation in the management of stimulant use disorders.
- Upon completion of the focus session, the participant will be able to articulate the value of artificial intelligence techniques in evaluating and repurposing existing medications in the management of stimulant use disorders.
Registration Rates
| Rate Description | Rate |
| ASAM Member | $29 |
| Non-Member | $39 |
| Associate Member | $19 |
| Resident Member* | $19 |
| Student Member* | $19 |
*Residents, Fellows-in-training, Interns, and Students must join ASAM to receive a discounted registration rate. Click here to become an ASAM member. National and Chapter membership dues apply. There is no charge for Students to become a Member, but verification of student status is required.
Membership Question? Call ASAM at 1.301.656.3920, email us, or view the ASAM website for more information.
Refunds & Cancellations
All ASAM eLearning Center refund requests must be made in writing to education@asam.org within 90 days of purchase. Those requesting refunds for courses that are in progress will receive partial refunds or e-Learning Center credit. Automatic full refunds will be made for any course with a live-course component that has been cancelled.
Registration Open: 05/06/2024 - 04/06/2027
User Access Closed: 05/06/2027
Session Instructions
- Click on the Contents tab to watch the on-demand recording.
- Click Complete Post Test to answer multiple choice questions. Participants will have 10 attempts to pass and must answer 4 out of 5 questions correctly.
- Click Complete Evaluation to provide valuable activity feedback. Scroll down on all questions as there may be answer options that expand past the size of the window.
- Click the button Claim Medical Credits in the box titled Claim Credits & Certificate. Choose the type of credit and click submit. Click the button View/Print Certificate to save or print your certificate. You can view/print your certificate at any time by visiting the ASAM eLearning Center, clicking Dashboard, and clicking Transcript/Achievements.
Need Assistance?
For assistance logging in, accessing activities, claiming credit, or for other questions or concerns, please check the FAQ page or e-mail Education@ASAM.org
ASAM is proud to offer Essential Accessibility to ensure our website is accessible and functional for all our learners while providing free assistive technology for people with the widest possible range of abilities.
Geetha A. Subramaniam
MD, DFAPA, DFAACAP
Geetha A. Subramaniam, MD, DFAPA, DFAACAP is the Deputy Director of the Center for Clinical Trials Network, at NIDA. In this role, she has been instrumental in developing research projects in a variety of topic areas, including addressing the prevention of substance abuse in adolescents, prevention and intervention of prescription stimulant misuse in youth. Previously, she was a full-time faculty member in the Division of Child Psychiatry at Johns Hopkins School of Medicine and the Associate Medical Director of Mountain Manor Treatment Center, Baltimore, MD, where she led clinical trials with adolescents with SUD and served as a preceptor to residents and fellows. She distinguished herself as a clinical and research expert in the assessment and treatment of adolescents and young adults with opioid use disorders. She is ABPN certified in General, Child, and Adolescent, and Addiction Psychiatry and a Distinguished Fellow of both the American Psychiatric Association and the American Academy of Child and Adolescent Psychiatry.
Madhukar H. Trivedi
MD
Madhukar Trivedi is Professor of Psychiatry, Chief of the Division of Mood Disorders, and Director of the Center for Depression Research and Clinical Care at UT Southwestern Medical Center. He earned his MBBS and MS in Baroda, India, completing his residencies in Psychiatry at University General Hospital, Baroda, India and Henry Ford Hospital, Detroit, Michigan. He completed his fellowship at UT Southwestern, where he now serves as Betty Jo Hay Distinguished Chair in Mental Health and Julie K. Hersh Chair for Depression Research and Clinical Care. Certified by the American Board of Psychiatry and Neurology, Dr. Trivedi is an established clinical and translational researcher with extensive experience serving as PI and Co-PI on several single and multi-site clinical trials funded by NIH, foundations and industry sponsors.
Dr. Trivedi’s research over the last 25 years has focused on understanding the neurobiology and psychology of depression and bipolar disorder, with a particular focus on developing an empirical basis for improving treatment of depression. Dr. Trivedi and his team have been involved in many of the pivotal studies involving the establishment of efficacy of antidepressant treatments (medications, psychotherapy, exercise, complimentary treatments, devices, etc.), examining next steps in treatment resistant depression to develop algorithms and guidelines, and developing and validating biomarkers in order to reach the goal of precision medicine for mood disorders. Among his most notable studies are the Establishing Moderators and Biosignatures of Antidepressant Response for Clinical Care (EMBARC) trial, Combining Medications to Enhance Depression Outcomes (CO-MED) trial, Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study, and the Texas Resilience Against Depression (T-RAD) study.
Does Disclose: Alkermes; monetary payment; Consulting Alto Neuroscience Inc; monetary payment & stock investments; Stockholder / Scientific Advisory Axsome Therapeutics, Inc.; N/A; Consulting Biogen MA Inc; monetary payment; Consulting Circular Genomics Inc.; stock investments; Consulting / Stockholder GH Research Limited; monetary payment; Consulting GreenLight VitalSign6; stock investments; Stockholder / Scientific Advisory Heading Health, Inc; n/a; Scientific Advisory; Janssen; n/a; Consulting Legion Health; stock investment; Stockholder / Scientific Advisory Mind Medicine (MindMed) Inc.; n/a; Consulting Neurocrine Biosciences Inc; n/a; Consulting Orexo US Inc; monetary payment; Consulting / Scientific Advisory Otsuka America Pharmaceutical, Inc.; monetary payment; Consulting Otsuka Canada Pharmaceutical Inc; monetary payment; Consulting Otsuka Pharmaceutical Development & Commercialization, Inc.; monetary payment; Consulting; Sage Therapeutics; monetary payment; Consulting Takeda Pharmaceutical Company Ltd.; n/a; Consutling WebMD; monetary payment; Consulting Sparian Biosciences; n/a; Consulting
Dr. Kathleen T. Brady
MD, PhD
Dr. Brady is an experienced clinical and translational researcher and has been conducting scientific investigations and clinical work in the field of addictions and psychiatric disorders for over 30 years. Her research focuses on pharmacotherapy of substance use disorders, comorbidity of psychiatric disorders and addictions (e.g., posttraumatic stress disorder and bipolar disorder), gender differences and women’s issues in addictions, and the neurobiologic connections between stress and addictions. She has received numerous federal research grants and has published over 300 peer-reviewed journal articles and co-edited 10 books. She is the Vice President for Research at the Medical University of South Carolina. She is the principal Investigator of MUSC’s Clinical and Translational Science Award (CTSA), Principal Investigator of the Southern Consortium Node of the NIDA-funded Clinical Trials Network and Director of MUSC’s Women’s Research Center. Her dedication to furthering research careers has attracted a number of junior investigators and clinicians. She has served at the President of the Association for Medical Education and Research in Substance Use Disorders (AMERSA), the American Academy of Addiction Psychiatry (AAAP) and is currently the President of the International Society of Addiction Medicine (ISAM).
Rong Xu, PhD
Professor
Case Western Reserve University
Rong Xu, PhD is Professor of Biomedical Informatics and Director of Center for Artificial Intelligence in Drug Discovery at Case Western Reserve University School of Medicine. Dr. Xu earned her BS degree in Biology from Peking University, M.S degree in Biology from Case Western Reserve University, M.S in Computer Science and Ph.D. in Biomedical Informatics both from Stanford University. Dr. Xu’s research falls into two broad categories: theoretical computer algorithm development and translational biomedical research. Her research interests in computer science focus on artificial intelligence, natural language processing, machine learning, data mining, statistical learning, systems biology, and other advanced computational techniques that can create, integrate, and analyze large amounts of heterogeneous and complex biological and health data. Her research interests in biomedical sciences include drug discovery, disease gene discovery, precision medicine, and health outcomes research. Dr. Xu has received several prestigious awards: (1) elected Fellow of American College of Medical Informatics; (2) The NIH Director’s New Innovator Award, (3) the Landon-AACR (American Association for Cancer Research) Innovator Award for Cancer Prevention Research, (4) the AMIA (American Medical Informatics Association) New Investigator award. Dr Xu has published in over 150 peer-reviewed research articles and her research works have been included in the CDC guidelines, contributed to FDA policy change, and featured in > 1000 news including New Yorker Times, NPR, ABC News, NBC News, CNN, WSJ, Forbes, USA Today, Fox News, and Scientific Americans.
Accreditation & Credit Designation Statements
Joint Accreditation Statement
In support of improving patient care, the American Society of Addiction Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physicians
The American Society of Addiction Medicine designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses
This activity awards 1.25 Nursing contact hours.
PAs
ASAM has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.25 AAPA Category 1 CME credits. Approval is valid until 05/06/2027. PAs should only claim credit commensurate with the extent of their participation.
Social Workers
As a Jointly Accredited Organization, ASAM is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. Regulatory boards are the final authority on courses accepted for continuing education credit. Social workers completing this course receive 1.25 general continuing education credits.
IPCE Credit
This activity was planned by and for the healthcare team, and learners will receive 1.25 Interprofessional Continuing Education (IPCE) credits for learning and change.
California Association for Drug/Alcohol Educators (CAADE)
This educational program is approved by CAADE: #CP40 999 1225.
California Association of DUI Treatment Centers (CADTP)
This educational program is approved by CADTP: #205.
California Consortium of Addiction Programs and Professionals (CCAPP)
This educational program is approved by CCAPP: #OS-20-330-1224.
Continuing Education Credits (CEUs)
Upon completion of the activity and online evaluation, all other participants may request a certificate of participation. Participants may submit this certificate of participation to their professional organization/institute as documentation for completing this accredited continuing activity.
Maintenance of Certification (MOC) or Continuing Certification Programs (CCP)
This activity meets the requirements for MOC/CCP for the following primary physician boards and for state licensing CME requirements. MOC Credit is only reported for ABA, ABP, ABIM, and ABS. By completing the online credit application and evaluation, the learner permits ASAM to report credits to the appropriate Board. Learn more.
- American Board of Medical Specialties (ABMS)
- American Board of Preventive Medicine (ABPM)
- American Board of Internal Medicine (ABIM)
- American Board of Pediatrics (ABP)
- American Board of Surgery (ABS)
- American Board of Psychiatry and Neurology (ABPN)
- American Board of Addiction Medicine (ABAM)
- Royal College of Physicians and Surgeons of Canada (RCPSC)
- Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons in Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Disclosure Information
In accordance with disclosure policies of ASAM and Joint Accreditation, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all CME/CE activities. These policies include mitigating all relevant financial relationships with ineligible companies for the Planning Committees and Presenters. All activity Planning Committee members and Presenters have disclosed all financial relationship information. The ASAM CE Committee has reviewed these disclosures and determined that the relationships are not inappropriate in the context of their respective presentations and are not inconsistent with the educational goals and integrity of the activity. Click here to view the full disclosure listing.
Key:
Complete
Next
Failed
Available
Locked